Abstract:Event Abstract Back to Event DNA vaccine encoding Hantavirus glycoprotein N-terminal, targeted to the major histocompatibility complex II compartment by lysosome-associated membrane protein, significantly elicits both specific humoral and cellular immune responses and induces immune protection against Hantavirus challenge in Balb/c mice Dongbo Jiang1, Yuanjie Sun1, Linfeng Cheng1, Kun Yang1* and Fanglin Zhang1* 1 The Forth Military Medical University, China Endogenous antigen encoded by conventional naked DNA was processed by antigen-presenting cells (APCs) and only presented to CD8+ T cell through forming peptide/MHCI (major histocompatibility complex type I molecules) complex. Whereas, antigen presentation by MHCII molecules and activation of CD4+ helper T cells are critical for the generation of effective immue response and long-term immune memory. Our previous studies showed DNA vaccine encoding SARS Coronavirus nucleocapsid (CoV-N), even epitope-based SARS CoV-N70-122 DNA vaccine with the lysosome-associated membrane protein (LAMP) as a chimera can not only elicit both humoral and cellular immune responses, but also promote a long-lasting T-cell memory response. Here, LAMP was as a key molecule trafficking DNA vaccine-encoding target protein to the MHC II compartment. Hantaan virus (HTNV), an old world Hantavirus, is mainly distributed in Asia. Haemorrhage fever with renal sydrome (HFRS) caused by HTNV is one of three Hantavirus-causing diseases (EN, HFRS and HPS). The fatality is among 3%-15%. In the past two years, sporatic cases of HPS obviously increased with a high fatality in the North America. There is no effective treatment to Hantavirus infection yet. Hence, vaccination prophylaxis is considered preferable solution against HV. Currently, inacitve HTNV vaccines are only applied in Asia, mainly China, Japan and South Korea. A continued reduction in HFRS was obseved while these vaccines distributed widely. However, short term of immunogenicity and low efficacy are disadvantages of inactive vaccine. development of a more effective vaccine of HTNV is of great need. Hantavirus glycoprotein N-terminal, named Gn, was reported that could induce neutralizing antibody production although with a low serum titer as natural infection. No study yet evaluates immune efficiency elicited by Gn as a vaccine. Therefore, we constructed DNA vaccine with HTNV Gn targeted to the MIIC by trafficking molecule LAMP. In this study, we have investigated the cellular and humoral immune responses in ex vivo and immune protection in vivo of immunized mice by DNA vaccine encoding HTNV glycoprotein N-terminal (Gn). The cDNA encoded HTNV Gn was acquired by PCR from a full-length HTNV M segment. First of all, effective expression of the proteins encoded by the DNA plasmid constructs in transfected 293 cells was confirmed. And then, Four groups of Balb/c mice were immunized with four different plasmids: ① pVAX1 vector with the Food and Drug Administration (FDA) document as a negative control. ② DNA encoding unmodified Gn as an endogenous antigen (pVAX-Gn); ③ DNA encoding Gn as a LAMP chimera targeted to the MIIC (pVAX-LAMP/Gn); ④ DNA encoding LAMP alone as a control (pVAX-LAMP) of pVAX-LAMP/Gn group. We tested specific antibody production in serum two weeks after each immunization by ELISA and neutralizing activity of antibody against HTNV by the cell microculture neutralization assay for humoral response evaluation. At the same time, we measured the peptide-specific IFN-γ secretion by ELISpot and specific CTL cytotoxicity against P815 cells which were loaded with Gn overlaping peptide-pool by LDH assay to evaluate cellular immune response. After Balb/c mice were immunized three times, animal protection experiment in vivo was also performed with Hantavirus challenging, and virus load in different tissues was detected by Sandwich ELISA and qRT-PCR. The results demonstrated that the immune responses differed markedly. Twice immunizations with pVAX-LAMP/Gn were sufficient to generate strong antibody response while no response in other groups. ELISpot analyses indicated that pVAX-LAMP/Gn elicited much greater IFN-γ response than pVAX-Gn. Whereas, pVAX-LAMP and pVAX induced very low levels, respectively. The cell microculture neutralization assay suggested that neutralizing antibodies against HTNV were producted in immunized mice with pVAX-LAMP/Gn and neutralizing titer in serum was the highest comparing with other three groups (p<0.05). The low level of neutralizing antibodies was detected in serum of immunized mice with pVAX-Gn, but the antibody neutralizing activity was undetectable in serum from pVAX or pVAX-LAMP group. For nonradioactive cytotoxicity assay, P815 cells were loaded with 83 overlaping peptides-pool of Gn as target cells. Among the experimental groups, splenocytes from mice immunized with the pVAX-LAMP/Gn showed higher specific cytotoxicity than that from mice immunized with the pPVAX-Gn at E/T ratios of 20:1, 10:1 and 5:1 (p<0.05). In contrast, no cytotoxicity against peptides loaded P815 cells in control mice immunized with pPVAX-LAMP or pVAX was detectable at each E/T ratios. Moreover, we investigated the protection efficacy in vivo after three times administration with naked DNA plasmids and carried out HTNV challenge. As no available animal model existed for HTNV challenge, which reflects the disease manifestations of severe HFRS, we made an observation of the Balb/c mice infected with HTNV 76-118 strain and established an evaluation system about animals infected with HTNV 76-118 before the animal protection experiment. We ran a set of programs (post-immunization viral intramuscular injection method) to infected the Balb/c mice with HTNV 76-118. Four groups of Balb/c mice were exposured to HTNV 76-118 at day 14 after third immunizations. And then, experimental mice were sacrificed and brain, heart, liver, spleen, lung and kidney were exteriorized after three days. Evaluation of viral load was performed by sandwich ELISA and qRT-PCR, and significant differences among the groups were observed. That is, the HTNV specific antigen could be detected in the brains and livers of the Balb/c mice immunized with pVAX-LAMP or pVAX, but undetected in that of all mice immunized with pVAX-LAMP/Gn or pVAX-Gn (p<0.01) . In summary, HTNV Gn usually cannot induce a strong immune response. However, Gn showed a strong immunogenicity to elicit both humoral and cellular responses with LAMP as a chimera. And results of protection assay in vivo indicated that the immune response established was HTNV specific and protective. These findings not only demonstrate that the LAMP as a trafficking molecule can introduce Gn to MHCII presenting pathway and significantly enhance HTNV specific immune response, but also suggest that the pVAX-LAMP/Gn as a DNA vaccine has potential application on clinic for HFRS immunoprophylaxis. Acknowledgements This work was supported by the National High Technology Research and Development Program 863 (No. 2006AA02A237) and the Military Key Scientific and Technological Project of 531 PR China (08G112) Keywords: Gene Vaccine, Hantaan Virus Gn, lysosome associated membrane protein, major histocompatibility complex II compartment, immune protection Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013. Presentation Type: Abstract Topic: Translational immunology and immune intervention Citation: Jiang D, Sun Y, Cheng L, Yang K and Zhang F (2013). DNA vaccine encoding Hantavirus glycoprotein N-terminal, targeted to the major histocompatibility complex II compartment by lysosome-associated membrane protein, significantly elicits both specific humoral and cellular immune responses and induces immune protection against Hantavirus challenge in Balb/c mice. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.01047 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 10 Jul 2013; Published Online: 22 Aug 2013. * Correspondence: Prof. Kun Yang, The Forth Military Medical University, Xi'an, China, yangkunkun@fmmu.edu.cn Prof. Fanglin Zhang, The Forth Military Medical University, Xi'an, China, flzhang@fmmu.edu.cn Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Dongbo Jiang Yuanjie Sun Linfeng Cheng Kun Yang Fanglin Zhang Google Dongbo Jiang Yuanjie Sun Linfeng Cheng Kun Yang Fanglin Zhang Google Scholar Dongbo Jiang Yuanjie Sun Linfeng Cheng Kun Yang Fanglin Zhang PubMed Dongbo Jiang Yuanjie Sun Linfeng Cheng Kun Yang Fanglin Zhang Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.

Phase 1 clinical trial of Hantaan and Puumala virus DNA vaccines delivered by needle-free injection

A comprehensive investigation of Glycoprotein-based nucleic acid vaccines for Hantaan Virus

Single dose recombinant VSV based vaccine elicits robust and durable neutralizing antibody against Hantaan virus

Construction and Evaluation of DNA Vaccine Encoding Hantavirus Glycoprotein N-terminal Fused with Lysosome-Associated Membrane Protein.

DNA Vaccines Encoding HTNV GP-Derived Th Epitopes Benefited from a LAMP-Targeting Strategy and Established Cellular Immunoprotection

© 2012 Landes Bioscience. Do not distribute. Immunogenicity of a multi-epitope DNA vaccine against hantavirus

Immunogenicity of a Multi-Epitope DNA Vaccine Against Hantavirus.

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial

Protective CD8+ T-cell response against Hantaan virus infection induced by immunization with designed linear multi-epitope peptides in HLA-A2.1/Kb transgenic mice

HSP70 gene fused with Hantavirus S segment DNA significantly enhances the DNA vaccine potency against hantaviral nucleocapsid protein in vivo.

Hantavirus Gc Induces Long-Term Immune Protection Via LAMP-targeting DNA Vaccine Strategy.

A recombinant pseudotyped lentivirus expressing the envelope glycoprotein of Hantaan virus induced protective immunity in mice

Pathogenicity of novel hantavirus isolate and antigenicity and immunogenicity of novel strain-based inactivated vaccine

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

Integrative Analysis of HTNV Glycoprotein Derived MHC II Epitopes by <i>In Silico</i> Prediction and Experimental Validation

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial

Construction and Immunological Characterization of CD40L or GM-CSF Incorporated Hantaan Virus Like Particle

Hantavirus-like Particles Generated in CHO Cells Induce Specific Immune Responses in C57BL/6 Mice

Incorporation of GM-CSF or CD40L Enhances the Immunogenicity of Hantaan Virus-Like Particles

Hybrid capture-based next-generation sequencing of New and Old World Orthohantavirus strains and wild-type Puumala isolates from humans and bank voles